Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shandong Weigao Blood Purification Products Co's EBIT per Share for the
three
months ended in Mar. 2026 was ¥0.33.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ¥1.44.
During the past 12 months, the average EBIT per Share Growth Rate of Shandong Weigao Blood Purification Products Co was -12.30% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 9.60% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 7.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
SHSE:603014'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 9.6 Med: 14.5 Max: 43.7
Current: 9.6
During the past 6 years, the highest 3-Year average EBIT per Share Growth Rate of Shandong Weigao Blood Purification Products Co was 43.70% per year. The lowest was 9.60% per year. And the median was 14.50% per year.
SHSE:603014's 3-Year EBIT Growth Rate is ranked better than 50.15% of 684
companies
in the Medical Devices & Instruments industry
Industry Median: 9.6
vs SHSE:603014: 9.60
Shandong Weigao Blood Purification Products Co (SHSE:603014) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Shandong Weigao Blood Purification Products Co EBIT per Share Related Terms
Shandong Weigao Blood Purification Products Co EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Weigao Blood Purification Products Co EBIT per Share Chart
Shandong Weigao Blood Purification Products Co Annual Data
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1.44
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Weigao Blood Purification Products Co (SHSE:603014) has a EBIT per Share of ¥1.44 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Shandong Weigao Blood Purification Products Co and its competitors. According to the industry distribution chart, Shandong Weigao Blood Purification Products Co ranks #341 out of 684 companies in the Medical Devices & Instruments industry, placing it in the top 49.9%.
Is Shandong Weigao Blood Purification Products Co's EBIT per Share too high?
Shandong Weigao Blood Purification Products Co's current EBIT per Share is ¥1.44. Based on the distribution chart, Shandong Weigao Blood Purification Products Co ranks #341 out of 684 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Shandong Weigao Blood Purification Products Co has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Shandong Weigao Blood Purification Products Co's EBIT per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Shandong Weigao Blood Purification Products Co ranks #341 out of 684 companies for EBIT per Share. This puts Shandong Weigao Blood Purification Products Co in the upper half of its industry. The industry median EBIT per Share is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.60, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Shandong Weigao Blood Purification Products Co and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shandong Weigao Blood Purification Products Co's current EBIT per Share is ¥1.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Weigao Blood Purification Products Co stock overvalued right now?
Shandong Weigao Blood Purification Products Co (SHSE:603014) has a current EBIT per Share of ¥1.44. The current EBIT per Share is ¥1.44. Shandong Weigao Blood Purification Products Co's overall GF Score™ is 39/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Shandong Weigao Blood Purification Products Co (SHSE:603014), the current EBIT per Share is ¥1.44 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603014 has been successfully added to your 
